Triage Test for All Oral DR-TB Regimen (TRiAD Study)

Inclusion Criteria:

1. Ambulant adults ≥ 18 years of age
2. Newly diagnosed PTB patients receiving less than 5 days of treatment since newdiagnosis:
3. Cohort 1: < 5 days of DR-TB treatment
4. Cohort 2: < 5 days of INH mono-resistant TB treatment preceding study entry forthe current TB episode, or
5. Sputum positive (smear and or culture) TB patients classified as failing first linetreatment
6. Any currently available Nucleic Acid Amplification Tests for drug-resistance detectionchanges/assay positive for M.tb infection with: Cohort 1: at least Rifampicin resistance Cohort 2: Rifampicin susceptible co-occurringwith INH, fluoroquinolone, ethionamide or aminoglycoside resistance (detected by XpertXDR) occurring alone or in combination
7. Capacity to provide informed consent
8. HIV infected and uninfected participants are allowed in the study. Participantsalready on ART will be allowed in the study provided the ART regimen in use has nocontraindications to the proposed TB drug regimen
9. Willing to have samples collected, stored indefinitely, and used for research purposes
10. Able to provide reasonable proof of identity (to satisfaction of study team member) ator prior to enrolment

Exclusion criteria:

1. Has a known severe allergy to any of the BPaL component drugs
2. Has DST showing infection with a strain resistant to any of the component drugs
3. Has TB meningitis, other central nervous system TB, or TB osteomyelitis; or
4. Is pregnant or breastfeeding
5. Is unable to take oral medications
6. Persons with any other medical condition, precluding study participation based oninvestigator judgement
7. Any co-existing condition that in the opinion of the attending clinician renders theparticipant unsuitable for participation in the study
8. Co-enrolment in other interventional research studies